WHWK News & Events

Reports Q1 revenue $0 vs. $7.14M last year. "This quarter reflects continued progress across our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third IND planned for HWK-206 mid-year," said Dave Lennon, CEO. "We remain focused on high quality execution as we build toward initial data anticipated in 1H 2027, with the goal of delivering meaningful benefits for patients."

Whitehawk Therapeutics announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research, AACR, Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA. "Across our three ADC programs, we have a consistent preclinical profile characterized by potent tumor regressions, high plasma stability and favorable tolerability in non-human primates, coupled with low systemic levels of free payload," said David Dornan, PhD, Chief Scientific Officer of Whitehawk Therapeutics. "These data support the potential for our next-generation bioconjugation and proprietary Carbon Bridge Cysteine Re-pairing linker-payload to deliver a differentiated, potentially best-in-class therapeutic index among TOP1i-based ADCs, which is fundamental to realizing the promise of ADCs for patients."